Stockreport

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial [Yahoo! Finance]

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com
PDF The open-label trial aims to assess the safety, tolerability, pharmacokinetics, and efficacy of ATI-2138 in AD patients over 12 weeks. Being conducted in the US, the [Read more]